Gujarat: Zydus Cadila now plans to check its Covid-19 vaccine for 5-12 age group – ET HealthWorld
After protecting adults and kids aged between 12 and 18 years below the continuing medical trials of its Covid-19 vaccine ZyKov-D, Zydus Cadila now plans to check its plasmid DNA vaccine for youngsters within the age group of 5 to 12 years.
The pharma main has already coated 800-plus youngsters in 12-18 years medical trials, “We will have a good amount of data on children in this age group. If everything goes well in terms of safety, the vaccine will potentially be approved for use in children aged 12 to 18 years,” mentioned Dr Sharvil Patel, managing director, Cadila Healthcare Restricted, the flagship firm of the Ahmedabad-based Zydus Cadila Group.
When requested concerning the firm’s plan to check the vaccine to be used in youngsters under the age of 12 years, Patel mentioned, “Yes, definitely. The vaccine development always happens in phases. Obviously, it starts with adults, followed by children in the 12-18 year age group and then you go towards younger kids aged five and above.”
Patel added that the following section of the trials could be to check the vaccine for youngsters aged 5 to 12. “This platform will be more useful for children because it will be devoid of any side effects that you get to see in many other vaccines. Another benefit of our vaccine is that it involves ‘needlefree’ administration,” he added.
Zydus is anticipating to obtain regulatory approval for the emergency use of its vaccine in adults by June-end or July.